Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Skin Neoplasms 2Keratosis, Actinic 2Cholangiocarcinoma 2Warts 1Skin Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms by Site 1Neoplasms 1Keloid 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Digestive System Diseases 1Constriction, Pathologic 1Cicatrix, Hypertrophic 1Carcinoma 1Biliary Tract Diseases 1Bile Duct Neoplasms 1Bile Duct Diseases 1Adenocarcinoma 1

Interventions

camrelizumab 3pembrolizumab 2Radiosurgery 2sinoporphyrin sodium 1penpulimab 1apatinib 1Tramadol 1S 1 (combination) 1Poly(ADP-ribose) Polymerase Inhibitors 1Photochemotherapy 1Pemetrexed 1Paclitaxel 1Morphine 1Injections 1Immune Checkpoint Inhibitors 1130-nm albumin-bound paclitaxel 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Parkinson Disease 4, Autosomal Dominant Lewy Body × Photochemotherapy × Clear all
NCT05386056 2022-11-28

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Peking University

Phase 2 Unknown
54 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡